

# Alcohol use disorders and the heart

Ed Day<sup>1</sup>  & James H. F. Rudd<sup>2</sup> 

Institute for Mental Health, School of Psychology, University of Birmingham, and Honorary Consultant in Addiction Psychiatry, Solihull Integrated Addiction Service, UK<sup>1</sup> and Division of Cardiovascular Medicine, University of Cambridge, Honorary Consultant Cardiologist, Addenbrooke's Hospital, Cambridge, UK<sup>2</sup>

## ABSTRACT

Alcohol use is an important preventable and modifiable cause of non-communicable disease, and has complex effects on the cardiovascular system that vary with dose. Observational and prospective studies have consistently shown a lower risk of cardiovascular and all-cause mortality in people with low levels of alcohol consumption when compared to abstainers (the 'J'-shaped curve). Maximum potential benefit occurs at 0.5 to one standard drinks (7–14 g pure ethanol) per day for women (18% lower all-cause mortality, 95% confidence interval (CI) = 13–22%) and one to two standard drinks (14–28 g ethanol) per day for men (17% lower all-cause mortality, 95% CI = 15–19%). However, this evidence is contested, and overall the detrimental effects of alcohol far outweigh the beneficial effects, with the risk of premature mortality increasing steadily after an average consumption of 10 g ethanol/day. Blood pressure (BP) is increased by regular alcohol consumption in a dose-dependent manner, with a relative risk for hypertension (systolic BP > 140 mm Hg or diastolic > 90 mm Hg) of 1.7 for 50 g ethanol/day and 2.5 at 100 g/day. Important reductions in BP readings can be expected after as little as 1 month of abstinence from alcohol. Heavy alcohol consumption in a binge pattern is associated with the development of acute cardiac arrhythmia, even in people with normal heart function. Atrial fibrillation is the most common arrhythmia associated with chronic high-volume alcohol intake, and above 14 g alcohol/day the relative risk increases 10% for every extra standard drink (14 g ethanol). Ethanol and its metabolites have toxic effects on cardiac myocytes, and alcoholic cardiomyopathy (ACM) accounts for a third of all cases of non-ischæmic dilated cardiomyopathy. Screening people drinking alcohol above low-volume levels and delivering a brief intervention may prevent the development of cardiovascular complications. Although people with established cardiovascular disease show improved outcomes with a reduction to low-volume alcohol consumption, there is no safe amount of alcohol to drink and patients with ACM should aim for abstinence in order to optimize medical treatment.

**Keywords** Alcohol, arrhythmia, cardiac, cardiomyopathy, cardiovascular, hypertension, mortality.

Correspondence to: Ed Day, Clinical Reader in Addiction Psychiatry, Institute for Mental Health, School of Psychology, University of Birmingham, Edgbaston, Birmingham B152TT, UK.

E-mail: e.j.day@bham.ac.uk

Submitted 8 April 2019; initial review completed 16 May 2019; final version accepted 29 May 2019

## INTRODUCTION

The harmful effects of alcohol on the heart began to appear in the medical literature in the 19th century. In 1886 the director of the Munich Institute of Pathology, Otto Bollinger, described an alcohol intake of up to 12 litres of beer per day in a series of 42 cases of cardiac hypertrophy, where many patients were employed by breweries or in liquor stores [1]. In his 1901 textbook of pathology he described what came to be known as 'Plethoric Munich Beer Heart':

'idiopathic cardiac hypertrophy usually with dilatation... most frequently found in certain forms of chronic alcoholism (beer drinkers), whereby plethora and toxic influences become effective as pathogenic factors'.

Alcohol use is one of the four most common preventable and modifiable causes of major non-communicable diseases [2], and the globalization of production and marketing of alcohol have increased both the amount of world-wide consumption and the harms associated with it [3]. The Alcohol Group of the Global Burden of Disease (GBD) study found that alcohol was the seventh leading risk factor for both deaths and disability-adjusted life years (DALYs), accounting for 2.2% [95% uncertainty interval (UI) 1.5–3.0] of age-standardized female deaths and 6.8% (5.8–8.0) of age-standardized male deaths [4]. In 2016 alcohol use led to 2.8 million deaths world-wide and was the leading risk factor for premature death and disability among people aged 15–49 years, with nearly 9% of all

attributable DALYs for men and more than 2% for women. By evaluating all associated relative risks for alcohol use, the GBD team found that drinking no alcohol minimized the overall risk to health [4]. However, although it is now well established that excessive alcohol consumption has an adverse effect on health and mortality [5], epidemiological studies have also suggested some potential benefits of low levels of consumption, including reductions in coronary heart disease events, ischaemic cerebrovascular events and cardiovascular and total mortality [6]. These beneficial effects are contested, and need to be set against by the negative effects of alcohol contributing to other diseases, accidents and injury and on society as a whole [7].

This review summarizes the epidemiological evidence for the impact of alcohol on the heart at low, medium and high levels, before focusing on clinical presentations of people who consume alcohol at higher levels or in a binge pattern. There is a particular focus on hypertension, cardiac arrhythmias and alcoholic cardiomyopathy. Consideration is given to the clinical presentation, pathological mechanisms, assessment, management and prognosis of each disorder, as well as the evidence of approaches to managing alcohol use disorders in this population.

## EPIDEMIOLOGY


There are difficulties in interpreting data relating to the health consequences of alcohol consumption. There is a lack of world-wide consensus as to the amount of alcohol in a standard alcoholic drink. In the United States a 'standard drink' contains 14 g of pure alcohol, but a 'unit' of alcohol in the United Kingdom is classified as 8 g of pure alcohol, and a standard drink in other countries may contain as much as 20 g of alcohol [8]. This review will adopt the US definition of a standard drink unless stated otherwise. Definitions of 'low', 'moderate' and 'hazardous' alcohol consumption have also varied, but most investigators have now settled on the following broad definition: low-risk drinking = two or fewer drinks/day for men and one drink/day or less for women, moderate-risk drinking = three to four drinks/day for men and two to three drinks/day for women, high-risk drinking = five or more drinks/day for men and four or more drinks/day for women and binge drinking = five or more drinks/occasion for men and four or more drinks/occasion for women.

Other factors complicating epidemiological studies of alcohol consumption include lack of adequate control for confounding factors such as cigarette smoking, general health and socio-economic status; problems with the accurate assessment of alcohol consumption (e.g. assessment over fewer than 30 days used to assess life-time risk of morbidity and mortality and a failure to assess both quantity and frequency of consumption); counting both former drinkers and occasional drinkers as abstainers (which


may make moderate drinkers seem healthier if ill health is the reason for abstinence or occasional drinking); and combining occasional drinkers with moderate drinkers [9]. In fact, Rehm has argued that methodological issues render the utility of cohort studies assessing the relationship between alcohol use and all-cause mortality as 'almost meaningless' [10].

## ALCOHOL AND CARDIOVASCULAR MORTALITY: THE J-SHAPED CURVE

Observational and prospective studies have consistently shown a lower risk of all-cause and cardiovascular mortality in people with low levels of alcohol consumption when compared with abstainers, with the highest risks occurring in people with high levels of consumption (the 'J-shaped' or 'U-shaped' curve) [5,6,11,12]. Xi and colleagues [5] examined the association between alcohol consumption and mortality risk in US adults, using data from the National Health Interview Surveys of 333 247 participants  $\geq 18$  years of age and categorizing participants according to self-reported alcohol consumption patterns. Compared with life-time abstainers, individuals who were classified as light or moderate consumers were at reduced risk of all-cause mortality and cardiovascular mortality, but that risk increased significantly with heavy alcohol consumption. This is seen in the J-shaped curves in Figs 1 and 2. A meta-analysis of 34 studies including more than a million people found a maximum potential benefit at half to one drink daily for women [18% lower all-cause mortality; 95% confidence interval (CI) = 13–22%] [13]. In men, maximal potential was seen at one to two drinks/day, with



**Figure 1** Dose-response association of current alcohol consumption with all-cause mortality [5]. This figure is used with permission of Elsevier, licence number 4591410186372. [Colour figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)]



**Figure 2** Dose-response association of current alcohol consumption with cardiovascular disease-specific (CVD) mortality [5]. This figure is used with the permission of Elsevier, licence number 4591410186372. [Colour figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)]

an associated reduction of 17% (95% CI = 15–19%) in all-cause mortality [13]. Consumption of more than 2.5 drinks/day in women and four drinks/day in men was associated with higher death rates in a dose-dependent manner.

Beverages such as red wine that are high in polyphenols have anti-oxidant, anti-inflammatory and antiplatelet effects. However, ethanol appears to be the main driver of potential health benefits at low doses and the toxic effects at high doses. Increased high-density lipoprotein (HDL), reduced plasma viscosity, decreased fibrinogen concentration, increased fibrinolysis, decreased platelet aggregation and coagulation and enhanced endothelial function are some of the potentially beneficial mechanisms [11,14].

One criticism of this literature is that low-volume drinkers may appear healthier only because the ‘abstainers’ with whom they are compared are not drinking because of pre-existing medical conditions (so-called ‘sick quitters’) or disease caused by prior high levels of alcohol consumption. A meta-analysis of 87 studies investigating alcohol use and mortality risk replicated the classic J-shaped curve, with low-volume drinkers (1.3–24.9 g ethanol/day) having reduced mortality risk [relative risk (RR) = 0.86, 95% CI = 0.83, 0.90] [15]. Occasional drinkers (< 1.3 g/day) had similar mortality risk (RR = 0.84, 95% CI = 0.79, 0.89) and former drinkers had elevated risk (RR = 1.22, 95% CI = 1.14, 1.31). However, after adjustment for abstainer biases and quality-related study characteristics, no significant reduction in mortality risk was observed for low-volume drinkers (RR = 0.97, 95% CI = 0.88, 1.07). Restriction of the analysis to higher-quality, bias-free studies also failed to show a reduced mortality risk for low-volume alcohol drinkers. Risk estimates for occasional drinkers were similar to those for low- and medium-volume drinkers [15].

Any cardioprotective effect of regular low-volume alcohol consumption disappears as soon as episodes of excessive drinking occur. One meta-analysis found that individuals with irregular heavy drinking episodes of  $\geq 60$  g pure alcohol per occasion ( $> 12\times/\text{year}$  but  $< 5\times/\text{week}$ ) had a 45% increased morbidity and mortality risk from ischaemic heart disease compared with individuals with a regular, moderate alcohol use pattern, even after adjusting for study type, subject age and smoking, and exclusion of former drinkers to control for sick quitters [16]. Overall, the detrimental effects of alcohol far outweigh the beneficial effects, and the risk of premature mortality increases steadily after 10 g average daily consumption in European populations [17].

## CLINICAL PRESENTATIONS RELATING TO THE HEART

When considering the heart and cardiovascular system, high doses of alcohol can have both acute (depression of cardiac contractility, cardiac rhythm disturbances, arterial hypertension, sudden death) and chronic effects (ventricular dysfunction, atrial dysfunction, arrhythmia, alcoholic cardiomyopathy and heart failure) [11]. In addition, chronic high doses of alcohol are associated with the development of hypertension, coronary and peripheral atherosclerosis, changes in lipid profile and an increased risk of all forms of stroke. Heavy use of alcohol is often accompanied by the use of other harmful drugs such as tobacco and cocaine, with synergistic deleterious effects [18,19].

## HYPERTENSION

Hypertension is most commonly defined as systolic blood pressure (BP)  $> 140$  mmHg or diastolic BP  $> 90$  mmHg. The 2015 GBD study put hypertension as the leading single risk factor for morbidity and mortality, responsible for 10.7 million deaths and 211.8 million DALYs world-wide [20]. Cross-sectional studies, cohort studies and meta-analytical reviews all point to BP being increased by regular alcohol consumption in a dose-dependent manner [6,21]. For example, a multinational meta-analysis showed a linear relationship between alcohol and BP, with a relative risk for hypertension of 1.7 for 50 g ethanol/day and 2.5 at 100 g/day [21]. However, gender is an important modifier of the alcohol threshold level for harm. The Physician’s Health Study found an apparent protective effect for women between two and four drinks/week and one drink/day, but the relationship in men was linear even at low levels of average consumption [22]. This gender-specific result does not have an obvious biological explanation, but one possibility is the finding that more binge drinking episodes occur among men at lower levels of

average consumption, and these are particularly related to increases in hypertension incidence and risk [23].

Assessment and treatment of alcohol-associated hypertension follows standard clinical guidelines [24], with ambulatory BP monitoring being used to confirm the diagnosis. A significant reduction of alcohol use is essential, alongside medications such as ACE inhibitors, calcium channel blockers and diuretics. Important improvements in BP readings can be expected after as little as 1 month of abstinence from alcohol, with one study demonstrating a 7.2 mmHg reduction in mean BP in previously heavy drinkers [25].

The link between alcohol consumption and hypertension makes it a key part of the World Health Organization (WHO) goals to reduce non-communicable disease mortality. In a meta-analysis of 36 trials, a decrease in alcohol intake reduced BP in people who drank more than two drinks/day, but not in those consuming two or fewer drinks/day [26]. The American Society of Hypertension and the International Society of Hypertension recommend that men limit their alcohol consumption to no more than two drinks a day and women to no more than one drink a day [27]. To put the importance of BP control into perspective at a population level, a 2-mmHg increase in BP increases mortality from stroke by 10% and from coronary artery disease (CAD) by 7% [28].

## ARRHYTHMIA

Heavy alcohol consumption in a binge pattern is associated with the development of acute cardiac arrhythmia, even in those with normal heart function. The term 'holiday heart' was coined by Ettinger in 1978 to describe 'an acute cardiac rhythm and or conduction disturbance associated with heavy ethanol consumption in a person without other clinical evidence of heart disease and disappearing without evident residual, with abstinence' [29]. The authors noted a seasonal rise in the incidence of arrhythmias during a period of traditional binge drinking (Christmas and New Year). Atrial fibrillation (AF) was the most common arrhythmia noted, but atrial flutter, junctional tachycardia, isolated premature ventricular complexes, isolated premature atrial complexes, paroxysmal atrial tachycardia and ventricular tachycardia were also described.

Alcohol may act together with coexistent electrolyte disturbance and/or acute illnesses such as infections to produce supraventricular arrhythmias [30]. Sudden death in alcohol misuse (SUDAM) is increasingly recognized, and case-series have described heavy drinkers who die suddenly with no autopsy findings other than fatty liver change [31]. There are several possible (but unproven) causes of such deaths, and a ventricular arrhythmia unmasked by persistent heavy alcohol use is one possibility. When compared with deaths due to sudden arrhythmic death syndrome,

the SUDAM group are significantly older and have a 10-fold greater incidence of fatty liver change [32]. Heavy alcohol consumption is associated with QT interval prolongation [33], and alcohol dependence commonly presents alongside polysubstance use and psychiatric morbidity where QT-prolonging medications may be part of the clinical picture, e.g. tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), lithium and methadone [34]. The risk of ventricular tachycardia and sudden cardiac death is lower in individuals with modest alcohol intake (two to six drinks/week) than those with high intake (21–35 drinks/week) and binge drinkers. This may be attributable to the protective effects of low-to-moderate alcohol consumption against coronary artery disease as described above [13]. Arrhythmias may also be manifestations of an underlying alcoholic cardiomyopathy, and so a holistic cardiovascular assessment is important.

Daily alcohol intake is associated with a shorter right atrial effective refractory period (AERP) and increased atrial flutter in patients less than 60 years old [35]. The shorter right AERP may allow the right atrium to sustain a rapid rate in response to an initiating rhythm or allow propagation of an appropriately timed premature atrial complex [35]. Atrial fibrillation is the most common arrhythmia associated with chronic high-volume alcohol intake. Above a safe threshold of approximately one drink/day the relative risk of AF increases 10% for each drink per day [36]. However, it appears that the relationship between chronic alcohol consumption and arrhythmias may be non-linear, involving complex interactions between dose, drinking pattern, age and sex [34]. For example, Psaty found alcohol was inversely related with incidence of AF in older adults with a lower level of drinking (two to three drinks/week) and a low incidence of binge drinking [37]. Acute alcohol withdrawal in chronic alcohol users can increase cardiac sympathetic activity and reduce both heart rate variability and baroreflex sensitivity, promoting cardiac arrhythmias [34].

Assessment and treatment of arrhythmia in patients who are heavy users of alcohol can be challenging if abstinence, or at least a significant reduction in intake, is not achieved [38]. Specifically, for atrial fibrillation, anticoagulation to reduce risk of stroke and ventricular rate control are central to the management strategy. In some cases, direct current cardioversion or electrophysiologically guided ablation techniques may be used, but ablation is known to be less successful in those who continue to drink alcohol, with higher AF relapse rates [39].

## ALCOHOLIC CARDIOMYOPATHY

Chronic excessive alcohol consumption is a leading cause of secondary dilated cardiomyopathy. However, partial or total recovery of cardiac function can occur if the disease



is diagnosed early and further alcohol intake is reduced or halted. Alcoholic cardiomyopathy (ACM) accounts for 33% of all cases of non-ischaemic dilated cardiomyopathy [40], and the prevalence is similar in males and females (alcohol consumption is higher in men, but women are more susceptible to its effects) [41].

Alcohol can lead to excess free-radical generation and oxidative stress through at least three mechanisms: ethanol metabolism to acetaldehyde and ethyl esters; effects on anti-oxidant proteins and enzymes; and activation or alteration of neurohormonal systems such as the sympathetic nervous system or the renin-angiotensin-aldosterone system (RAAS) [14]. Cardiac myocytes are excitable cells with complex signalling structures, and as such are highly sensitive to oxidative stress. Experimental models of chronic heart damage have many limitations, but over time heavy alcohol use directly impairs myocardial function by interfering with calcium homeostasis, mitochondrial function, and the structure and function of contractile proteins [41]. Myocyte apoptosis and necrosis occurs, and although there is a low rate of regeneration after cell death, repair mechanisms involving hypertrophy of remaining cells can initially offset the effect of myocyte death [11]. However, reduced levels of myofibrillar proteins, combined with the expression of different isoforms of myosin, result in depressed contraction [41]. These changes eventually translate into increased left ventricular dilatation and mass, thinning and left ventricular dysfunction [34]. Genetic variants in certain proteins/enzymes, variability in nutrition, ethnic and sex differences may also influence the occurrence of ACM [14,41,42] (see Fig. 3).


One-third of men with a total life-time dose of ethanol of more than 5 kg/kg have echocardiographic evidence of impaired diastolic filling, an effect that persists after correction for multiple confounders. This is proposed as the earliest sign of subclinical ACM [11,43]. Long-term high alcohol consumption is also associated with systolic dysfunction in a dose-dependent way. Prospective studies have shown that chronic alcohol consumption of more than 100 g/day in men and 80 g/day in women over a period of 10 years is associated with dose-dependent effects on left ventricular function [44].

Regular, heavy alcohol use can lead to ACM, characterized by dilation and impaired contraction of one or both ventricles in the presence of normal or reduced ventricular wall thickness, with no other identified cause of cardiomyopathy [45]. ACM is defined as an acquired dilated cardiomyopathy associated with long-term heavy alcohol consumption (> 80 g per day over a period of at least 5 years). Typical histological findings are myofibrillar necrosis and fibrosis, with reduced myofibrils and giant mitochondria, findings which do not differentiate ACM from other forms of dilated cardiomyopathy.

Presenting symptoms relate to the reduction in cardiac output and are the same as chronic cardiac failure of any aetiology, i.e. shortness of breath on exertion, bilateral pitting oedema, fatigue, mental confusion, oliguria and nocturia. Physical examination may reveal a raised jugular venous pressure, third and/or fourth heart sound and a systolic murmur, and possibly a tachyarrhythmia such as AF. Diagnosis requires a long history of significant alcohol use and exclusion of other causes of dilated cardiomyopathy. Blood tests such as gamma-glutamyl transferase (GGT), mean corpuscular volume (MCV), carbohydrate-deficient transferrin (CDT) and ethyl-gluconide may help to diagnose alcohol use disorder, coexisting liver disease and monitor abstinence. N-terminal pro-B-type natriuretic peptide (NT pro-BNP) levels are increasingly used to make a diagnosis of heart failure in patients with breathlessness, and may be helpful. A chest X-ray may show cardiomegaly, pulmonary congestion and pleural effusions, depending on disease severity. An electrocardiogram may reveal coexisting atrial fibrillation, along with non-specific ST and T-wave changes. There are no tell-tale electrocardiogram (ECG) features of ACM that can differentiate it from other causes of cardiomyopathy. Echocardiography is mandatory for diagnosis and to exclude other causes of heart failure. Typically, it shows biventricular dilatation and systolic and diastolic dysfunction. Occasionally, cardiac magnetic resonance imaging (MRI) is needed to confirm the diagnosis if echocardiographic images are suboptimal. Exclusion of contributing coronary artery disease with coronary angiography is often required.

The prevailing wisdom regarding treatment of ACM is total abstinence from alcohol to allow potential recovery of cardiac function. Unfortunately, no blood or imaging biomarkers of potential reversibility have been identified. Abstinence has been associated with improved LV function in small observational studies in some patients (e.g. [46]). However, Nicolas *et al.* found significant cardiac improvement in both those achieving abstinence and those reducing consumption to less than 60 g ethanol/day, but cardiac function deteriorated in those who did not change drinking [47]. As there is no safe amount of alcohol to drink, it is best to aim for abstinence in the first instance.

After abstinence, treatment of ACM should include beta-blockers, ACE inhibitors, angiotensin receptor antagonists and diuretics, following standard guidelines [48]. Patients with persistent severe ventricular dysfunction despite optimized pharmacological therapy should be evaluated for implantable cardioverter defibrillator (ICD) insertion and heart transplant if considered appropriate. Eating a balanced diet is important, and any nutritional deficiencies should be corrected. Vitamin supplementation with vitamin B12, vitamin B6 and folate may be needed, particularly for those with sustained heavy alcohol use. In the largest published follow-up study of patients with



**Figure 3** A summary of the effects of acute and chronic alcohol consumption on the heart and cardiovascular system. The blue boxes and arrows represent influences on susceptibility to alcohol-related harm. Adapted from Piano 2017 [14] and Mirijello *et al.* 2017 [41]. [Colour figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)]

ACM ( $n = 94$ , median follow-up 59 months), approximately one-third had a poor prognosis, whereas two-thirds remained clinically stable. Atrial fibrillation, QRS width-120 msec, and the absence of beta-blocker therapy were associated with a worse outlook [49].

### MANAGEMENT OF ALCOHOL USE DISORDER AND CARDIAC DISORDERS

Interventions for alcohol use disorders exist along a spectrum [50]. Screening people drinking at 'at-risk' level and delivering a brief intervention may prevent the development of cardiovascular complications such as hypertension and arrhythmias. However, despite a strong evidence base for such interventions [51], they are rarely implemented in routine medical practice [52]. Excessive consumption of alcohol is one of a number of modifiable causes of health problems in the developed world. As medical care moves towards a chronic disease model there have been calls to incorporate effective behaviour change strategies into medical practice, and a number have been identified for changing alcohol use [53].

Motivational Interviewing (MI) is a counselling style that aims to address the problem of ambivalence about change, and is both person-centred and directional in its focus on goals such as changes in health behaviours [54]. In a systematic review and meta-analysis of the efficacy of MI throughout medical settings, 63% of the main outcome comparisons yielded statistically significant advantages favouring MI [55]. MI produced a statistically significant and positive impact on amount of alcohol consumed, but this did not include any studies of populations with cardiac

disease. Unlike other areas of medicine (e.g. surgery [56] or liver failure [57]), there is little published literature on interventions tailored to reducing alcohol use in populations with cardiovascular disease.

Psychosocial interventions are efficacious in treating alcohol use disorder [58], and are the mainstay of treatment. The predominant treatment goal for alcohol dependence has traditionally been abstinence. Acamprosate and naltrexone have been shown to reduce the risk of returning to drinking when prescribed in conjunction with psychosocial interventions [59], and neither have cardiac-related contraindications. Disulfiram works in a different manner (inhibition of acetaldehyde dehydrogenase enzyme leading to a build-up of acetaldehyde and associated unpleasant physical effects), and its deterrent effect can improve the outcome of treatment when a third party is involved to assist with compliance [60]. At the usual prescribed dose of 200–250 mg/day, the disulfiram-alcohol interaction varies from mild flushing to distressing nausea, headache, dizziness and chest tightness. Fatal cases reported in the medical literature suggest that cardiac causes of death are common [61]. In the early days of disulfiram use, patients were given a test dose of alcohol, and most patients developed some ECG changes during the reaction (e.g. QT-prolongation). Hypotension and hypertension are also common, and the potentially fatal outcome of a disulfiram-alcohol reaction in a patient with heart disease means that disulfiram is not usually offered to this group.

Abstinence from alcohol is likely to produce the best outcomes for established hypertension, arrhythmia and cardiomyopathy, but may not be a feasible or acceptable goal for many patients. Intervention strategies have now

broadened to include reduction of alcohol intake, and even alcohol-dependent people with loss of control over the past 12 months can reduce their drinking [62]. Treatment programmes aiming at harm reduction help to establish self-determined controlled drinking and use this as a bridge to long-term abstinence [63,64]. Interventions aiming at reducing total alcohol consumption and/or modifying the drinking pattern are associated with positive effects in harmful, hazardous or alcohol-dependent drinkers [65].

## PROGNOSIS

### Secondary prevention

People with established cardiovascular disease show improved outcomes with a reduction to low-volume drinking. A meta-analysis of 16 351 patients with a previous diagnosis of CVD found a J-shaped curve with maximal risk at two drinks/day [66]. A similar relationship exists between alcohol and cardiovascular mortality in patients who have experienced a myocardial infarction [67], and low levels of alcohol are also associated with less atherosclerotic progression in coronary artery bypass grafts post-coronary artery bypass grafting (CABG) [68].

### Mortality rates

The mortality risk may decline threefold if a person with a usual alcohol intake of 96 g ethanol/day cuts down to 36 g ethanol/day compared with a constant daily intake of 60 g ethanol/day [69]. In one long-term prospective cohort study ( $n = 850$ ), 15% heavy drinking patients (defined as 50 g ethanol or more per drinking occasion or daily drinking) died after 10 years and 39.1% after 20 years, compared to low-volume drinkers consuming less than 50 g ethanol per drinking occasion less than once per month (5.3% at 10 years and 19.7% at 20 years) [70]. In contrast, significantly more relapsed patients (73%) died prematurely at the mean age of 48 years (mainly from heart attack or heart failure) compared to those without relapses (30%) in the 16-year observation period.

### Conclusions

Although low-volume alcohol consumption (one drink/day or less for women and two drinks for men) may confer some benefit in terms of reduced risk of ischaemic heart disease [71], alcohol use at higher levels is associated with increased cardiovascular risk and premature mortality. Occasional binge drinking (more than five drinks within a few hours, with intoxication as intended consequence) reverses any protection associated with low-volume alcohol consumption. The main cardiovascular effects of long-term alcohol consumption are hypertension, cardiac arrhythmia, cardiomyopathy and heart failure. Treatment for alcohol

use disorder is best focused on abstinence from alcohol, although gains are often achieved by significant reduction in alcohol consumption or changes in pattern of drinking.

### Declaration of interests

None.

### Acknowledgements

J.H.E.R. is part-supported by the NIHR Cambridge Biomedical Research Centre, the British Heart Foundation, HEFCE, the EPSRC and the Wellcome Trust.

### References

1. Meister P. *Mythology in Pathology? The Munich Beer Heart Revisited: United States and Canadian Academy of Pathology*; 2003. Available at: <http://uscapknowledgehub.org/index.htm?92nd/companion09h3.htm> (accessed 16 June 2019).
2. World Health Organization (WHO) *Global Status Report on Alcohol and Health 2014*. Geneva: WHO Press; 2014.
3. Rehm J, Mathers C., Popova S., Thavorncharoensap M., Teerawattananon Y., Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. *Lancet* 2009; **373**: 2223–33.
4. Global Burden of Disease Study (GBD) 2016 Alcohol Collaborators, Griswold M. G., Fullman N., Hawley C., Arian N., Zimsen S. R. M., *et al.* Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2018; **392**: 1015–35.
5. Xi B., Veeranki S. P., Zhao M., Ma C., Yan Y., Mi J. Relationship of alcohol consumption to all-cause, cardiovascular, and cancer-related mortality in U.S. adults. *J Am Coll Cardiol* 2017; **70**: 913–22.
6. O'Keefe E. L., DiNicolantonio J. J., O'Keefe J. H., Lavie C. J. Alcohol and CV health: Jekyll and Hyde J-curves. *Prog Cardiovasc Dis* 2018; **61**: 68–75.
7. Mukamal K., Lazo M. Alcohol and cardiovascular disease. *BMJ* 2017; **356**: j1340.
8. Kalinowski A., Humphreys K. Governmental standard drink definitions and low-risk alcohol consumption guidelines in 37 countries. *Addiction* 2016; **111**: 1293–8.
9. Stockwell T., Greer A., Fillmore K., Chikritzhs T., Zeisser C. How good is the science? *BMJ* 2012; **344**: e2276.
10. Rehm J. Why the relationship between level of alcohol-use and all-cause mortality cannot be addressed with meta-analyses of cohort studies. *Drug Alcohol Rev* 2019; **38**: 3–4.
11. Fernández-Solà J. Cardiovascular risks and benefits of moderate and heavy alcohol consumption. *Nat Rev Cardiol* 2015; **12**: 576–87.
12. Goel S., Sharma A., Garg A. Effect of alcohol consumption on cardiovascular health. *Curr Cardiol Rep* 2018; **20**: 19.
13. Di Castelnuovo A., Costanzo S., Bagnardi V., Donati M. B., Iacoviello L., de Gaetano G. Alcohol dosing and total mortality in men and women: an updated meta-analysis of 34 prospective studies. *Arch Intern Med* 2006; **166**: 2437–45.
14. Piano M. R. Alcohol's effects on the cardiovascular system. *Alcohol Res* 2017; **38**: 219–41.
15. Stockwell T., Zhao J., Panwar S., Roemer A., Naimi T., Chikritzhs T. Do 'moderate' drinkers have reduced mortality risk? A systematic review and meta-analysis of alcohol consumption and all-cause mortality. *J Stud Alcohol Drugs* 2016; **77**: 185–98.

16. Roerecke M., Rehm J. Irregular heavy drinking occasions and risk of ischemic heart disease: a systematic review and meta-analysis. *Am J Epidemiol* 2010; **171**: 633–44.
17. Rehm J., Zatonksi W., Taylor B., Anderson P. Epidemiology and alcohol policy in Europe. *Addiction* 2011; **106**: 11–9.
18. Chan L.-N., Anderson G. D. Pharmacokinetic and pharmacodynamic drug interactions with ethanol (alcohol). *Clin Pharmacokinet* 2014; **53**: 1115–36.
19. Hart C. L., Davey Smith G., Gruer L., Watt G. C. M. The combined effect of smoking tobacco and drinking alcohol on cause-specific mortality: a 30 year cohort study. *BMC Public Health* 2010; **10**: 789.
20. Forouzanfar M. H., Afshin A., Alexander L. T., Anderson H. R., Bhutta Z. A., Biryukov S., *et al.* Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 2016; **388**: 1659–724.
21. Taylor B., Irving H. M., Baliunas D., Roerecke M., Patra J., Mohapatra S., *et al.* Alcohol and hypertension: gender differences in dose–response relationships determined through systematic review and meta-analysis. *Addiction* 2009; **104**: 1981–90.
22. Sesso H. D., Cook N. R., Buring J. E., Manson J. E., Gaziano J. M. Alcohol consumption and the risk of hypertension in women and men. *Hypertension* 2008; **51**: 1080–7.
23. Rehm J., Sempos C. T., Trevisan M. Average volume of alcohol consumption, patterns of drinking and risk of coronary heart disease—a review. *J Cardiovasc Risk* 2003; **10**: 15–20.
24. National Clinical Guideline Centre (NCGC) *Hypertension: The Clinical Management of Primary Hypertension in Adults*. London: NCGC; 2011.
25. Aguilera M. T., de la Sierra A., Coca A., Estruch R., Fernández-Solà J., Urbano-Márquez A. Effect of alcohol abstinence on blood pressure. *Hypertension* 1999; **33**: 653–7.
26. Roerecke M., Kaczorowski J., Tobe S. W., Gmel G., Hasan O. S. M., Rehm J. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. *Lancet Public Health* 2017; **2**: e108–e120.
27. Weber M. A., Schiffrin E. L., White W. B., Mann S., Lindholm L. H., Kenerson J. G., *et al.* Clinical practice guidelines for the management of hypertension in the community. *J Clin Hypertens* 2014; **16**: 14–26.
28. Prospective Studies Collaboration Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* 2002; **360**: 1903–13.
29. Ettinger P. O., Wu C. E., Cruz C. D. L., Weisse A. B., Sultan A. S., Regan T. J. Arrhythmias and the ‘Holiday Heart’: alcohol-associated cardiac rhythm disorders. *Am Heart J* 1978; **95**: 555–62.
30. Kupari M., Koskinen P. Alcohol consumption of patients with supraventricular tachyarrhythmias other than atrial fibrillation. *Alcohol Alcohol* 1991; **26**: 199–206.
31. Templeton A. H., Carter K. L. T., Sheron N., Gallagher P. J., Verrill C. Sudden unexpected death in alcohol misuse—an unrecognized public health issue? *J Environ Res Public Health* 2009; **6**: 3070–81.
32. Sorkin T., Sheppard M. N. Sudden unexplained death in alcohol misuse (SUDAM) patients have different characteristics to those who died from sudden arrhythmic death syndrome (SADS). *Forens Sci Med Pathol* 2017; **13**: 278–83.
33. Kino M., Imamitchi H., Morigutchi M., Kawamura K., Takatsu T. Cardiovascular status in asymptomatic alcoholics, with reference to the level of ethanol consumption. *Br Heart J* 1981; **46**: 545–51.
34. George A., Figueredo V. M. Alcohol and arrhythmias: a comprehensive review. *J Cardiovasc Med* 2010; **11**: 221–8.
35. Marcus G. M., Smith L. M., Whiteman D., Tseng Z. H., Badhwar N., Lee B. K., *et al.* Alcohol intake is significantly associated with atrial flutter in patients under 60 years of age and a shorter right atrial effective refractory period. *Pacing Clin Electrophysiol* 2008; **31**: 266–72.
36. Larsson S. C., Drca N., Wolk A. Alcohol consumption and risk of atrial fibrillation: a prospective study and dose–response meta-analysis. *J Am Coll Cardiol* 2014; **64**: 281–9.
37. Psaty B. M., Manolio T. A., Kuller L. H., Kronmal R. A., Cushman M., Fried L. P., *et al.* Incidence of and risk factors for atrial fibrillation in older adults. *Circulation* 1997; **96**: 2455–61.
38. Kodama S., Saito K., Tanaka S., Horikawa C., Saito A., Heianza Y., *et al.* Alcohol consumption and risk of atrial fibrillation, A meta-analysis. *Am J Coll Cardiol* 2011; **57**: 427–36.
39. Takigawa M., Takahashi A., Kuwahara T., Takahashi Y., Okubo K., Nakashima E., *et al.* Impact of alcohol consumption on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation. *J Am Heart Assoc* 2016; **5**: e004149.
40. Laonigro I., Correale M., Di Biase M., Altomare E. Alcohol abuse and heart failure. *Eur J Heart Fail* 2009; **11**: 453–62.
41. Mirijello A., Tarli C., Vassallo G. A., Sestito L., Antonelli M., d’Angelo C., *et al.* Alcoholic cardiomyopathy: what is known and what is not known. *Eur J Intern Med* 2017; **43**: 1–5.
42. Piano M. R., Phillips S. A. Alcoholic cardiomyopathy: pathophysiological insights. *Cardiovasc Toxicol* 2014; **14**: 291–308.
43. Urbano-Márquez A., Fernández-Solà J. Effects of alcohol on skeletal and cardiac muscle. *Muscle Nerve* 2004; **30**: 689–707.
44. Urbano-Marquez A., Estruch R., Navarro-Lopez F., Grau J. M., Mont L., Rubin E. The effects of alcoholism on skeletal and cardiac muscle. *N Engl J Med* 1989; **320**: 409–15.
45. George A., Figueredo V. M. Alcoholic cardiomyopathy: a review. *J Cardiac Fail* 2011; **17**: 844–9.
46. Guillo P., Mansourati J., Maheu B., Etienne Y., Provost K., Simon O., *et al.* Long-term prognosis in patients with alcoholic cardiomyopathy and severe heart failure after total abstinence. *Am J Cardiol* 1997; **79**: 1276–8.
47. Nicolás J. M., Fernández-Solà J., Estruch R., Paré J. C., Sacanella E., Urbano-Márquez A., *et al.* The effect of controlled drinking in alcoholic cardiomyopathy. *Ann Intern Med* 2002; **136**: 192–200.
48. Ponikowski P., Voors A. A., Anker S. D., Bueno H., Cleland J. G. E., Coats A. J. S., *et al.* 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2016; **18**: 891–975.
49. Guzzo-Merello G., Segovia J., Dominguez F., Cobo-Marcos M., Gomez-Bueno M., Avellana P., *et al.* Natural history and prognostic factors in alcoholic cardiomyopathy. *JACC Heart Fail* 2015; **3**: 78–86.
50. US Department of Health and Human Services (USDHHS) Office of the Surgeon General. Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health. Washington, DC: USDHHS; 2016.



51. National Institute for Health and Clinical Excellence (NICE) *Alcohol-use Disorders: Preventing Harmful Drinking*. NICE Public Health Guidance. London: NICE; 2010.
52. Day E., Copello A., Hull M. Assessment and management of alcohol use disorders. *BMJ* 2015; **350**: h715.
53. Michie S., Whittington C., Hamoudi Z., Zarnani F., Tober G., West R. Identification of behaviour change techniques to reduce excessive alcohol consumption. *Addiction* 2012; **107**: 1431–40.
54. Rollnick S., Heather N., Bell A. Negotiating behaviour change in medical settings: the development of brief motivational interviewing. *J Ment Health* 1992; **1**: 25–37.
55. Lundahl B., Moleni T., Burke B. L., Butters R., Tollefson D., Butler C., *et al.* Motivational interviewing in medical care settings: A systematic review and meta-analysis of randomized controlled trials. *Patient Educ Couns* 2013; **93**: 157–68.
56. Fernandez A. C., Claborn K. R., Borsari B. A systematic review of behavioural interventions to reduce preoperative alcohol use. *Drug Alcohol Rev* 2015; **34**: 508–20.
57. Khan A., Tansel A., White D. L., Kayani W. T., Bano S., Lindsay J., *et al.* Efficacy of psychosocial interventions in inducing and maintaining alcohol abstinence in patients with chronic liver disease: a systematic review. *Clin Gastroenterol Hepatol* 2016; **14**: 191–202, e194.
58. National Collaborating Centre for Mental Health *Alcohol-Use Disorders: The NICE Guideline on Diagnosis, Assessment and Management of Harmful Drinking and Alcohol Dependence*. London: The British Psychological Society and The Royal College of Psychiatrists; 2011.
59. Kranzler H. R. Evaluation and treatment of anxiety symptoms and disorders in alcoholics. *J Clin Psychiatry* 1996; **57**: 15–21.
60. Jørgensen C. H., Pedersen B., Tønnesen H. The efficacy of disulfiram for the treatment of alcohol use disorder. *Alcohol Clin Exp Res* 2011; **35**: 1749–58.
61. Chick J. Safety issues concerning the use of disulfiram in treating alcohol dependence. *Drug Saf* 1999; **20**: 427–35.
62. Witkiewitz K. Lapses following alcohol treatment: modeling the falls from the wagon. *J Stud Alcohol Drugs* 2008; **69**: 594–604.
63. Mann K., Aubin H. J., Witkiewitz K. Reduced drinking in alcohol dependence treatment, what is the evidence? *Eur Addict Res* 2017; **23**: 219–30.
64. van Amsterdam J., van den Brink W. Reduced-risk drinking as a viable treatment goal in problematic alcohol use and alcohol dependence. *J Psychopharmacol* 2013; **27**: 987–97.
65. Charlet K., Heinz A. Harm reduction—a systematic review on effects of alcohol reduction on physical and mental symptoms. *Addict Biol* 2017; **22**: 1119–59.
66. Costanzo S., Di Castelnuovo A., Donati M. B., Iacoviello L., de Gaetano G. Alcohol consumption and mortality in patients with cardiovascular disease: a meta-analysis. *J Am Coll Cardiol* 2010; **55**: 1339–47.
67. Carter M. D., Lee J. H., Buchanan D. M., Peterson E. D., Tang F., Reid K. J., *et al.* Comparison of outcomes among moderate alcohol drinkers before acute myocardial infarction to effect of continued versus discontinuing alcohol intake after the infarct. *Am J Cardiol* 2010; **105**: 1651–4.
68. Mukamal K. J., Girotra S., Mittleman M. A. Alcohol consumption, atherosclerotic progression, and prognosis among patients with coronary artery bypass grafts. *Am Heart J* 2006; **151**: 368–72.
69. Rehm J., Roerecke M. Reduction of drinking in problem drinkers and all-cause mortality. *Alcohol Alcohol* 2013; **48**: 509–13.
70. Gual A., Bravo E., Lligoña A., Colom J. Treatment for alcohol dependence in Catalonia: health outcomes and stability of drinking patterns over 20 years in 850 patients. *Alcohol Alcohol* 2009; **44**: 409–15.
71. Krenz M., Korthuis R. J. Moderate ethanol ingestion and cardiovascular protection: from epidemiologic associations to cellular mechanisms. *J Mol Cell Cardiol* 2012; **52**: 93–104.